Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by MGO One Seven LLC

MGO One Seven LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 70.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,195 shares of the biopharmaceutical company's stock after buying an additional 4,639 shares during the period. MGO One Seven LLC's holdings in Gilead Sciences were worth $1,034,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Wells Fargo & Company upped their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Friday. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $109.43.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the transaction, the chief financial officer now directly owns 171,223 shares of the company's stock, valued at $17,502,415.06. This represents a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold a total of 302,785 shares of company stock valued at $30,540,875 over the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $3.17 during trading on Monday, reaching $106.34. The company's stock had a trading volume of 9,453,782 shares, compared to its average volume of 7,514,594. The company has a 50-day moving average price of $109.19 and a two-hundred day moving average price of $98.48. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market cap of $132.41 billion, a PE ratio of 287.41, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the company earned ($1.32) earnings per share. The business's revenue was down .3% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.